Rachel Haurwitz, Ph.D.
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception in 2011. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. She currently serves as a board member of the Biotechnology Innovation Organization (BIO). Rachel is an inventor on several patents and patent applications covering multiple CRISPR-based technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
Barbara McClung, J.D.
Barbara serves as Chief Legal Officer and Corporate Secretary for Caribou Biosciences, where she is responsible for all legal functions, including intellectual property strategy and portfolio management, contracts, corporate transactions, board governance, and employment law. In addition, the Company's human resources function reports to Barbara. Prior to joining Caribou in 2015, she headed the legal functions at Intarcia Therapeutics, Inc. and Cygnus, Inc. Barbara began her career as a patent attorney with E. I. du Pont de Nemours and Company, and then joined Chiron Corporation where she was patent counsel for Chiron’s vaccine division. Barbara is a member of the California, Delaware, and Pennsylvania bars, and is a registered patent attorney before the United States Patent and Trademark Office. Barbara received her B.A. from the University of California, San Diego, and her J.D. from the University of Pennsylvania Law School.
Steven Kanner, Ph.D.
Steve is the Chief Scientific Officer of Caribou Biosciences responsible for the Company’s therapeutic discovery, research, and development activities. Before joining Caribou in 2017, Steve was most recently Vice President, Head of Biology, at Arrowhead Pharmaceuticals leading a department in discovery of RNAi therapeutics for oncology, genetic diseases, and other indications. Prior to Arrowhead Pharmaceuticals, he served in various positions of increasing responsibility in both oncology and inflammation drug discovery at Bristol-Myers Squibb, Agensys/Astellas, and Astex Pharmaceuticals. Steve has authored over 80 publications in both peer-reviewed journals and books, and is an inventor on numerous U.S. and foreign patents and patent applications. Steve earned his undergraduate degree in Genetics from the University of California, Berkeley, and his Ph.D. in Immunology and Microbiology from the University of Miami’s Miller School of Medicine. He did his post-doctoral fellowship at the University of Virginia.
Cherry Thomas, M.D.
Cherry is the Senior Vice President of Clinical Development at Caribou Biosciences and she leads and oversees the advancement of the Company’s allogeneic cell therapy candidates. She most recently served as Vice President of Clinical Development at Array Biopharma of the oncology division. She previously served in leadership positions with increasing responsibility at multiple companies including as Executive Director of Clinical Development at BeiGene, Ltd. where she oversaw development programs aimed to evaluate an immuno-oncology combination therapy targeting solid tumors. She also held the role of Vice President of Clinical Development at Jounce Therapeutics where she managed the company’s early development program and guided clinical trial execution. In addition, Cherry held leadership clinical development and medical roles in oncology at Bristol-Myers Squibb, Novartis, GlaxoSmithKline, and Amgen. Cherry earned her B.A. from the University of California, Los Angeles; her M.A. from Johns Hopkins University; and her M.D. from the University of California, Irvine. She completed an internship at the University of California, Los Angeles and a residency at the University of Michigan.
Elaine serves as the Vice President of Regulatory Affairs and Quality Assurance for Caribou Biosciences. She brings more than 30 years of experience in regulatory affairs and quality assurance with biotechnology, pharmaceutical, and medical device companies in all phases of development in multiple therapeutic areas, including immunology (vaccines), oncology, ophthalmology and dermatology. Previously, Elaine was Executive Director of Regulatory Affairs at Dynavax Technologies during which time she lead the regulatory effort for HEPLISAV-B® and its US BLA approval and European licensing applications. Elaine has held a variety of regulatory and quality positions of increasing responsibility at Allergan, Santen Pharmaceuticals, PrisMedical, and Dey Laboratories. Elaine holds a B.S. in Biology from the University of California, Irvine.
Chris Fuller, Ph.D.
As the Vice President of Informatics, Chris leads the informatics and software efforts at Caribou Biosciences. He has a background managing diverse teams in developing instrumentation, medical devices, software, and microfluidic systems. Prior to joining Caribou in 2014, he held research and leadership positions in consulting, startup, and established company environments, including Signature Bioscience, MDS Sciex, and Triple Ring Technologies. He led the development of the CellKey instrument for MDS Sciex from its inception through to product launch. Chris is an inventor of multiple patents and patent applications. He received his B.S. and M.S. degrees in Electrical Engineering from the Georgia Institute of Technology and a Ph.D. in Bioinformatics from the University of California, San Francisco.
Scott Gradia, Ph.D.
Scott serves as the Vice President of Platform Research and directs the molecular biology lab capabilities, facility operations, and platform research and development at Caribou Biosciences. In this role, Scott is responsible for the Company's new genome editing technology development efforts. Before joining Caribou in 2015, Scott founded and led the MacroLab, a DNA cloning and protein purification facility on the University of California, Berkeley campus. Scott received his B.S. in Genetics from Iowa State University and his Ph.D. in Genetics from Thomas Jefferson University, where he was awarded the Weintraub Graduate Student Award for his work describing the biochemistry of DNA mismatch repair and its role in hereditary colon cancer. He performed his post-doctoral work as a Damon-Runyon fellow at the University of California, Berkeley, studying structural biology.
As Vice President of Human Resources, Cindy leads the human resources function at Caribou Biosciences. Prior to joining Caribou, she held similar positions at StemCells, Inc. and Cygnus Therapeutics where she also managed the facilities and EHS functions. Cindy started her career with Procter and Gamble in manufacturing management after completing her B.S. degree in Industrial Engineering and Operations Research from the University of California, Berkeley.
Justin Skoble, Ph.D.
Justin is the Vice President of Technical Operations at Caribou Biosciences responsible for developing the Company’s clinical trial materials. Before joining Caribou in 2019, Justin was most recently Chief Development Officer at Actym Therapeutics Inc., leading the development of microbial therapeutics for oncology. Prior to Actym, he served in various positions of increasing responsibility in immune-oncology and vaccine development at Aduro Biotech, Anza Therapeutics, and Cerus Corporation. Justin has authored over 12 publications in peer-reviewed journals and is an inventor on numerous U.S. and foreign patents and patent applications. Justin earned his undergraduate degree in Biology from Vassar College, and his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. He did his post-doctoral fellowship at the University of California, San Francisco.